Humacyte Q2 FY26 net loss narrows to $36.8 million; Symvess revenue more than quadruples to $406,000

Reuters2026/08/12 11:06

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Humacyte posted a net loss of USD 36.8 million; loss per share narrowed to USD 0.16 from USD 0.24.
Revenue rose 34.88% to 406,000; Symvess sales more than doubled to 406,000.
Operating loss narrowed to USD 27 million from USD 29.73 million; R&D expense fell to USD 18.14 million from USD 22.01 million.
Cash, cash equivalents and restricted cash totaled USD 80.3 million; June public offering raised USD 57.5 million in gross proceeds.
Dialysis access Phase 3 interim data showed ATEV beat AV fistula; sBLA filing planned in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120700PRIMZONEFULLFEED9808172) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Humacyte Q2 FY26 net loss narrows to $36.8 million; Symvess revenue more than quadruples to $406,000

You may also like

Crypto prices